Teva initiates phase III trial of long-acting schizophrenia injection

Using technology from Medincell, the Israeli generic drugmaker will investigate the long-acting antipsychotic potential of olanzapine, which was originally launched by Eli Lilly years ago, in a phase III study.


Israeli generic drugmaker Teva is attempting to develop the substance olanzapine into a long-acting schizophrenia treatment, improving upon the daily tablet administration now.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs